BRIDGEWATER, N.J., Oct. 20, 2020 /PRNewswire/ -- Insmed
Incorporated (Nasdaq: INSM), a global biopharmaceutical company on
a mission to transform the lives of patients with serious and rare
diseases, today announced that it will release its third quarter
2020 financial results on Thursday, October
29, 2020.
Insmed management will host a conference call for investors
beginning at 8:30 a.m. ET on Thursday,
October 29, 2020 to discuss the financial results and
provide a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (833) 340-0284 (domestic) or (236)
712-2425 (international) and referencing conference ID number
8292364. The call will also be webcast live on the company's
website at www.insmed.com.
A replay of the conference call will be accessible approximately
two hours after its completion through November 12, 2020 by dialing (800) 585-8367
(domestic) or (416) 621-4642 (international) and referencing
conference ID number 8292364. A webcast of the call will also be
archived for 90 days under the Investor Relations section of the
company's website at www.insmed.com.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product, ARIKAYCE®
(amikacin liposome inhalation suspension), is the first and only
therapy approved in the United
States for the treatment of refractory Mycobacterium
avium complex (MAC) lung disease as part of a combination
antibacterial drug regimen for adult patients with limited or no
alternative treatment options. MAC lung disease is a chronic,
debilitating condition that can cause severe and permanent lung
damage. Insmed is also advancing brensocatib, a novel oral
reversible inhibitor of dipeptidyl peptidase 1 with therapeutic
potential in bronchiectasis and other inflammatory diseases, and
treprostinil palmitil inhalation powder, a treprostinil prodrug
formulated as a dry powder for inhalation, which may offer a
differentiated product profile for rare pulmonary disorders,
including pulmonary arterial hypertension. For more
information, visit www.insmed.com.
Contact:
Investors:
Argot Partners
Laura Perry or Heather Savelle
(212) 600-1902
Insmed@argotpartners.com
Media:
Mandy Fahey
Senior Director, Corporate Communications
Insmed
(732) 718-3621
Amanda.fahey@insmed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2020-financial-results-conference-call-on-thursday-october-29-2020-301155176.html
SOURCE Insmed Incorporated